Results 31 to 40 of about 187,751 (309)

CMS Reimbursement Reform [PDF]

Journal of General Internal Medicine, 2015
T o the Editor: In a well-designed study, Gidwani and Bhattacarya report that the incidence of venous thromboembolism (VTE) following elective hip and knee replacements decreased after Centers for Medicare and Medicaid Services (CMS) reimbursement reform.
Stephanie Parks, Taylor, David J, Ecker, Brice, Taylor   +2 more
openaire   +2 more sources

Review of Gastrointestinal Capsule Robots: Materials, Actuation, Diagnostics, and Therapeutics

Advanced Science, EarlyView.
This review examines gastrointestinal capsule robots through a systems engineering lens, covering shell materials, actuation and localization strategies, diagnostic modalities, therapeutic interventions, and commercialization status. By mapping the complete technological chain from fabrication to clinical deployment, this work identifies critical gaps ...
Zengsheng Li, Zhongguo Ren, Yiliang Lin, Xianfeng Xia, Tianlong Li, Kai Fung Chan, Philip Wai Yan Chiu, Wei Peng Yong, Mengmeng Sun   +8 more
wiley   +1 more source

CAR‐Engineered Cell Therapies Beyond Cancer: Reprogramming Fibrosis and Immune‐Mediated Inflammation

Advanced Science, EarlyView.
CAR‐engineered cell therapies are expanding beyond cancer toward immune resetting, pathological‐cell clearance, matrix remodeling, and microenvironmental reprogramming in autoimmune, inflammatory, and fibrotic diseases. This Review compares CAR‐T, CAR‐macrophage, and CAR‐NK platforms and proposes controllable spatiotemporal reprogramming to align ...
Peng Jun Xu, Zhou Jing Zhang, Jing Jin, Hai Yuan Xu, Ya Xin Gu, Qian Qian Yang, You Lang Zhou   +6 more
wiley   +1 more source

Economic evaluation of biosimilars for reimbursement purposes – what, when, how?

Journal of Market Access & Health Policy, 2020
Background: Limited previous research and guidelines on the design of economic evaluation for biosimilars have led to unresolved methodological questions on how to assess biosimilars.
Evelien Moorkens, Hannah Broux, Isabelle Huys, Arnold G. Vulto, Steven Simoens   +4 more
doaj   +1 more source

Tumor Exposomics: A New Paradigm for Individualized Continuous Exposure Monitoring

Advanced Science, EarlyView.
Tumor exposomics integrates continuous monitoring of environmental exposures, endogenous biological responses, and behavioral factors within a unified temporal framework. By combining multimodal sensing technologies with AI‐enabled causal modeling, this emerging paradigm reconstructs exposure‐damage trajectories and supports individualized dynamic risk
Kaicheng Shen, Weiyi Wang, Yang Wang, Yiqiang Wu, Xiaohong Liu, Wei Zhang, Juanjuan Ou   +6 more
wiley   +1 more source

Pricing of orphan drugs in oncology and rare diseases

Journal of Market Access & Health Policy, 2020
Objective: The objective of this paper is to determine an upper price limit for an orphan drug by taken a broader perspective and, including also other monetary and non-monetary values for the society.
Mark Nuijten, Stefano Capri
doaj   +1 more source

Too Complex to Choose? The Role of Heuristics in Shaping Farmers' Willingness to Pay for Income Stabilization Tool in Italy

Agribusiness, EarlyView.
ABSTRACT European agriculture is increasingly exposed to economic instability driven by extreme weather events, market volatility, and geopolitical tensions. To manage these growing risks, farmers are encouraged to adopt innovative risk management strategies such as the Income Stabilization Tool (IST), which offers protection against severe income ...
Alice Stiletto, Ruggiero Rippo, Samuele Trestini, Elisa Giampietri, Roberta Raffaelli, Simone Cerroni   +5 more
wiley   +1 more source

Examining confidential wholesale margin estimates in European countries for the price negotiation of patented drugs in Germany: a statistical model

Health Economics Review
Background Based on the legal framework laid down in section 130b (9) of Book V of the German Social Code, various criteria are relevant for the negotiated price for new patented drugs in Germany. European reference prices (ERPs) are one criterion.
Iris an der Heiden, Guido Schiffhorst, Laura Müller, Martin Albrecht, Arne Bartol, Stefanie Wiberny   +5 more
doaj   +1 more source

Affordable and equitable access to subsidised outpatient medicines? Analysis of co-payments under the Additional Drug Package in Kyrgyzstan

International Journal for Equity in Health, 2019
Background Out-of-pocket (OOP) payments can constitute a major barrier for affordable and equitable access to essential medicines. Household surveys in Kyrgyzstan pointed to a perceived growth in OOP payments for outpatient medicines, including those ...
Sabine Vogler, Peter Schneider, Guillaume Dedet, Hanne Bak Pedersen   +3 more
doaj   +1 more source

One‐Year Healthcare Utilization and Costs After Emergency Department Encounters for Uncomplicated Appendicitis: A Statewide Observational Study

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Objective Non‐operative management with antibiotics has emerged as an alternative to appendectomy for uncomplicated appendicitis. This study compared one‐year healthcare costs and utilization outcomes after operative versus non‐operative management of uncomplicated appendicitis using statewide administrative data.
Andrew C. Meltzer, Michael Makutonin, Taylor Gorak, Aditya Loganathan, Jack A. Meltzer, Avi Dor   +5 more
wiley   +1 more source